| |
Drug-Eluting Stent
|
Bare Metal Stent
|
PValue
|
|---|
|
N
|
19,103
|
16,335
| |
|---|
|
Age (years)
|
64.1
|
63.2
|
< 0.001
|
|
Male Sex (%)
|
70.8
|
70.6
|
0.72
|
|
Race/Ethnicity (%)
| | |
< 0.001
|
|
Asian
|
9.8
|
7.0
| |
|
Black
|
5.3
|
5.3
| |
|
Hispanic
|
9.4
|
8.4
| |
|
White, non-Hispanic
|
65.8
|
72.1
| |
|
Other
|
9.7
|
7.3
| |
|
Comorbidities (%)
| | | |
|
Diabetes
|
33.8
|
26.2
|
< 0.001
|
|
Hypertension
|
68.5
|
49.6
|
< 0.001
|
|
Prior MI
|
13.0
|
11.1
|
< 0.001
|
|
PCI Indication:
| | |
< 0.001
|
|
STEMI
|
16.0
|
27.5
| |
|
NSTEMI
|
28.0
|
19.3
| |
|
Stable or unstable angina
|
57.3
|
54.8
| |
|
Prior PCI
|
19.1
|
14.1
|
< 0.001
|
|
Prior CABG
|
5.7
|
5.3
|
0.12
|
|
Congestive Heart Failure
|
4.6
|
3.4
|
< 0.001
|
|
Prior Stroke
|
1.6
|
1.2
|
0.005
|
|
Peripheral Arterial Disease
|
4.3
|
3.3
|
< 0.001
|
|
Glomerular Filtration Rate
| | |
< 0.001
|
|
> 90
|
15.0
|
16.2
| |
|
60 - 89
|
39.7
|
33.4
| |
|
30 - 59
|
21.5
|
15.2
| |
|
15 - 30
|
1.9
|
1.3
| |
|
< 15 or HD
|
0.7
|
0.5
| |
|
Unknown
|
21.1
|
33.3
| |
|
Systemic Malignancy
|
5.7
|
5.8
|
0.75
|
|
Prior Gastrointestinal Bleeding
|
2.3
|
1.8
|
< 0.001
|
|
Chronic Lung Disease
|
18.3
|
21.9
|
< 0.001
|
|
Medications
| | | |
|
β-Blockers
|
50.0
|
40.1
|
< 0.001
|
|
Clopidogrel
|
12.7
|
6.3
|
< 0.001
|
|
Statin
|
51.7
|
34.8
|
< 0.001
|
|
ACE-I/ARB
|
41.9
|
27.8
|
< 0.001
|
|
Warfarin
|
3.8
|
3.0
|
< 0.001
|
- Abbreviations: MI, myocardial infarction; STEMI, ST-elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft surgery.
